UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007664
Receipt number R000009028
Scientific Title Oral propranolol therapy for infantile hemangiomas
Date of disclosure of the study information 2012/05/01
Last modified on 2017/03/23 10:09:49

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Oral propranolol therapy for infantile hemangiomas

Acronym

Oral propranolol therapy for infantile hemangiomas

Scientific Title

Oral propranolol therapy for infantile hemangiomas

Scientific Title:Acronym

Oral propranolol therapy for infantile hemangiomas

Region

Japan


Condition

Condition

Infantile hemangiomas

Classification by specialty

Plastic surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To assess the efficasy and safety of oral propranolol treatment for infantile hemangiomas

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change in size of infantile hemangiomas and side effects of propranolol treatment

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Oral propranolol

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

0 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.Proliferating infantile hemangiomas
2.Informed consent

Key exclusion criteria

1.Patient who has a severe complication without infantile hemangiomas
2.Patient with the past of serious side effect by the propranolol drug
3.Patient with asthma or carbohydrate metabolism
4.Patient who was considered ineligible by the investigators

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Ichiro Hashimoto

Organization

Tokushima University Hospital

Division name

Plastic and Reconstructive Surgery

Zip code


Address

2-50-1 Kuramoto-tyo, Tokushima, Tokushima

TEL

088-633-7296

Email

ichiro.h@tokushima-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Kazuhide Mineda

Organization

Tokushima University Hospital

Division name

Plastic and Reconstructive Surgery

Zip code


Address

2-50-1 Kuramoto-tyo, Tokushima, Tokushima

TEL

088-633-7296

Homepage URL


Email

mineda.k528@gmail.com


Sponsor or person

Institute

Tokushima University Hospital

Institute

Department

Personal name



Funding Source

Organization

Tokushima University Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 05 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 04 Month 14 Day

Date of IRB


Anticipated trial start date

2012 Year 05 Month 01 Day

Last follow-up date

2016 Year 03 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 04 Month 04 Day

Last modified on

2017 Year 03 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009028


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name